新月生物制药公司（Crescent Biopharma Inc.）已向美国证券交易委员会提交实益所有权初始声明。根据申报文件披露，公司首席科学官简·平卡斯（Jan Pinkas）被确认为实益所有权人。该文件完整版本可通过下方链接获取。
根据美国证监会规定，上市公司高管及持股超5%的股东需通过特定表格披露实益所有权变动。此次申报标志着平卡斯作为新任高管首次完成法定披露程序。作为生物医药企业的核心科研负责人，其持股动向通常受到投资者关注。文件链接如下：
（此处保留原始文件链接位置）
注：本报道依据美国证监会EDGAR系统公示文件（档案号：0001104659-25-068102）编制，原始信息由新月生物制药公司全权负责。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.